SAN DIEGO--(BUSINESS WIRE)--March 28, 2006--Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company focused on therapies for gastrointestinal (GI) diseases and disorders, today announced the U.S. commercial launch of ZEGERID(R) (omeprazole/sodium bicarbonate) Capsules 40 mg/1100 mg and 20 mg/1100 mg, an immediate-release proton pump inhibitor (PPI). ZEGERID Capsules were approved by the U.S. Food and Drug Administration (FDA) on February 27, 2006.
